PCSA

Processa Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

0.188

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.1951

Open

0.1868

VWAP

0.19

Vol

2.09M

Mkt Cap

9.45M

Low

0.1815

Amount

394.60K

EV/EBITDA(TTM)

Total Shares

2.86M

2.54M

EV/OCF(TTM)

P/S(TTM)

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-0.080

-92.23%

-0.080

-89.19%

-0.060

-80%

Estimates Revision

The market is revising No Change the revenue expectations for Processa Pharmaceuticals, Inc. (PCSA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -34.83%.

EPS Estimates for FY2025

Revise Downward

-47.19%

In Past 3 Month

Stock Price

Go Down

-34.83%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast PCSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCSA is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.188

Low

2.00

Averages

2.00

High

2.00

Current: 0.188

Low

2.00

Averages

2.00

High

2.00

H.C. Wainwright

Raghuram Selvaraju

Buy

downgrade

$2 -> $1

2025-09-02

New

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$2 -> $1

2025-09-02

New

downgrade

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Processa Pharmaceuticals to $1 from $2 and keeps a Buy rating on the shares. The firm cites equity dilution from the strategic investment for the target cut.

H.C. Wainwright

Buy

downgrade

$6 -> $2

2025-06-30

Reason

H.C. Wainwright

Price Target

$6 -> $2

2025-06-30

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Processa Pharmaceuticals to $2 from $6 and keeps a Buy rating on the shares after the company recently announced that it had raised a total of $7M in gross proceeds from an equity financing involving the sale of common shares, pre-funded warrants and warrants to purchase common stock. The equity financing lengthens the runway through key clinical development milestone, but the firm is lowering its price target to account for dilution, the analyst noted.

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

2024-12-05

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

2024-12-05

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

2024-10-03

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

2024-10-03

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Processa Pharmaceuticals Inc (PCSA.O) is -0.55, compared to its 5-year average forward P/E of -3.59. For a more detailed relative valuation and DCF analysis to assess Processa Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.59

Current PE

-0.55

Overvalued PE

0.75

Undervalued PE

-7.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00